Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature

K. L. Wallace, R. L. Filipek, R. M. La Hoz, J. C. Williamson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

What is known and objective: Voriconazole has significant drug interactions due to metabolism by CYP enzymes. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone are not well described. Case description: An 84-year-old male was started on voriconazole for a fungal brain abscess. He was readmitted due to clinical failure thought to be the result of subtherapeutic voriconazole concentrations. Dexamethasone was identified as a potential cause due to its induction of CYP enzymes. This interaction was substantiated by sequential troughs that demonstrated a rise in voriconazole concentrations as dexamethasone was tapered off. What is new and conclusion: Therapeutic drug monitoring for patients on voriconazole and dexamethasone is essential to prevent suboptimal clinical outcomes.

Original languageEnglish (US)
Pages (from-to)441-443
Number of pages3
JournalJournal of Clinical Pharmacy and Therapeutics
Volume41
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Dexamethasone
Brain Abscess
Enzyme Induction
Drug Monitoring
Drug Interactions
Voriconazole
Enzymes

Keywords

  • dexamethasone
  • drug–drug interaction
  • fungal brain abscess
  • therapeutic drug monitoring
  • voriconazole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone : case report and review of the literature. / Wallace, K. L.; Filipek, R. L.; La Hoz, R. M.; Williamson, J. C.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 41, No. 4, 01.08.2016, p. 441-443.

Research output: Contribution to journalArticle

@article{a65bbb959074462d9a31b82cfc87cd00,
title = "Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature",
abstract = "What is known and objective: Voriconazole has significant drug interactions due to metabolism by CYP enzymes. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone are not well described. Case description: An 84-year-old male was started on voriconazole for a fungal brain abscess. He was readmitted due to clinical failure thought to be the result of subtherapeutic voriconazole concentrations. Dexamethasone was identified as a potential cause due to its induction of CYP enzymes. This interaction was substantiated by sequential troughs that demonstrated a rise in voriconazole concentrations as dexamethasone was tapered off. What is new and conclusion: Therapeutic drug monitoring for patients on voriconazole and dexamethasone is essential to prevent suboptimal clinical outcomes.",
keywords = "dexamethasone, drug–drug interaction, fungal brain abscess, therapeutic drug monitoring, voriconazole",
author = "Wallace, {K. L.} and Filipek, {R. L.} and {La Hoz}, {R. M.} and Williamson, {J. C.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/jcpt.12401",
language = "English (US)",
volume = "41",
pages = "441--443",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone

T2 - case report and review of the literature

AU - Wallace, K. L.

AU - Filipek, R. L.

AU - La Hoz, R. M.

AU - Williamson, J. C.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - What is known and objective: Voriconazole has significant drug interactions due to metabolism by CYP enzymes. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone are not well described. Case description: An 84-year-old male was started on voriconazole for a fungal brain abscess. He was readmitted due to clinical failure thought to be the result of subtherapeutic voriconazole concentrations. Dexamethasone was identified as a potential cause due to its induction of CYP enzymes. This interaction was substantiated by sequential troughs that demonstrated a rise in voriconazole concentrations as dexamethasone was tapered off. What is new and conclusion: Therapeutic drug monitoring for patients on voriconazole and dexamethasone is essential to prevent suboptimal clinical outcomes.

AB - What is known and objective: Voriconazole has significant drug interactions due to metabolism by CYP enzymes. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone are not well described. Case description: An 84-year-old male was started on voriconazole for a fungal brain abscess. He was readmitted due to clinical failure thought to be the result of subtherapeutic voriconazole concentrations. Dexamethasone was identified as a potential cause due to its induction of CYP enzymes. This interaction was substantiated by sequential troughs that demonstrated a rise in voriconazole concentrations as dexamethasone was tapered off. What is new and conclusion: Therapeutic drug monitoring for patients on voriconazole and dexamethasone is essential to prevent suboptimal clinical outcomes.

KW - dexamethasone

KW - drug–drug interaction

KW - fungal brain abscess

KW - therapeutic drug monitoring

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84976577480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976577480&partnerID=8YFLogxK

U2 - 10.1111/jcpt.12401

DO - 10.1111/jcpt.12401

M3 - Article

C2 - 27207573

AN - SCOPUS:84976577480

VL - 41

SP - 441

EP - 443

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 4

ER -